ITUB20153714A1 - Thymosine alfa 1 for use in the treatment of cystic fibrosis. - Google Patents

Thymosine alfa 1 for use in the treatment of cystic fibrosis.

Info

Publication number
ITUB20153714A1
ITUB20153714A1 ITUB2015A003714A ITUB20153714A ITUB20153714A1 IT UB20153714 A1 ITUB20153714 A1 IT UB20153714A1 IT UB2015A003714 A ITUB2015A003714 A IT UB2015A003714A IT UB20153714 A ITUB20153714 A IT UB20153714A IT UB20153714 A1 ITUB20153714 A1 IT UB20153714A1
Authority
IT
Italy
Prior art keywords
thymosine
alfa
treatment
cystic fibrosis
cystic
Prior art date
Application number
ITUB2015A003714A
Other languages
Italian (it)
Inventor
Luigina Romani
Enrico Garaci
Original Assignee
Luigina Romani
Enrico Garaci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luigina Romani, Enrico Garaci filed Critical Luigina Romani
Priority to ITUB2015A003714A priority Critical patent/ITUB20153714A1/en
Priority to RU2017128749A priority patent/RU2724932C2/en
Priority to AU2016217473A priority patent/AU2016217473B2/en
Priority to KR1020177024477A priority patent/KR102648036B1/en
Priority to JP2017559940A priority patent/JP6762524B2/en
Priority to PCT/IT2016/000027 priority patent/WO2016129005A1/en
Priority to BR112017016205-9A priority patent/BR112017016205A2/en
Priority to EP20212130.7A priority patent/EP3865149A1/en
Priority to CA2976062A priority patent/CA2976062A1/en
Priority to US15/549,073 priority patent/US10478474B2/en
Priority to ES16714558T priority patent/ES2844578T3/en
Priority to EP16714558.0A priority patent/EP3256150B1/en
Priority to CN201680009244.3A priority patent/CN107466236B/en
Publication of ITUB20153714A1 publication Critical patent/ITUB20153714A1/en
Priority to US16/593,226 priority patent/US11524056B2/en
Priority to JP2020143640A priority patent/JP7102475B2/en
Priority to JP2022109285A priority patent/JP2022133412A/en
Priority to US18/050,890 priority patent/US20230173031A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
ITUB2015A003714A 2015-02-09 2015-09-18 Thymosine alfa 1 for use in the treatment of cystic fibrosis. ITUB20153714A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
ITUB2015A003714A ITUB20153714A1 (en) 2015-09-18 2015-09-18 Thymosine alfa 1 for use in the treatment of cystic fibrosis.
EP20212130.7A EP3865149A1 (en) 2015-02-09 2016-02-04 Thymosin alpha 1 for use in treatment of cystic fibrosis
ES16714558T ES2844578T3 (en) 2015-02-09 2016-02-04 Thymosin alfa 1 for use in the treatment of cystic fibrosis
KR1020177024477A KR102648036B1 (en) 2015-02-09 2016-02-04 Thymosin alpha 1 for use in the treatment of cystic fibrosis
JP2017559940A JP6762524B2 (en) 2015-02-09 2016-02-04 Timocin α1 for use in the treatment of cystic fibrosis
PCT/IT2016/000027 WO2016129005A1 (en) 2015-02-09 2016-02-04 Thymosin alpha 1 for use in treatment of cystic fibrosis
BR112017016205-9A BR112017016205A2 (en) 2015-02-09 2016-02-04 thymosin alpha 1 for use in the treatment of cystic fibrosis
RU2017128749A RU2724932C2 (en) 2015-02-09 2016-02-04 Thymosin alpha-1 for use in treating cystic fibrosis
CA2976062A CA2976062A1 (en) 2015-02-09 2016-02-04 Thymosin alpha 1 for use in treatment of cystic fibrosis
US15/549,073 US10478474B2 (en) 2015-02-09 2016-02-04 Thymosin alpha 1 for use in treatment of cystic fibrosis
AU2016217473A AU2016217473B2 (en) 2015-02-09 2016-02-04 Thymosin alpha 1 for use in treatment of cystic fibrosis
EP16714558.0A EP3256150B1 (en) 2015-02-09 2016-02-04 Thymosin alpha 1 for use in treatment of cystic fibrosis
CN201680009244.3A CN107466236B (en) 2015-02-09 2016-02-04 Use of thymosin alpha 1 for the treatment of cystic fibrosis
US16/593,226 US11524056B2 (en) 2015-02-09 2019-10-04 Thymosin alpha 1 for use in treatment of cystic fibrosis
JP2020143640A JP7102475B2 (en) 2015-02-09 2020-08-27 Thymosin α1 for use in the treatment of cystic fibrosis
JP2022109285A JP2022133412A (en) 2015-02-09 2022-07-06 THYMOSIN α1 FOR USE IN TREATMENT OF CYSTIC FIBROSIS
US18/050,890 US20230173031A1 (en) 2015-02-09 2022-10-28 Thymosin alpha 1 for use in treatment of cystic fibrosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2015A003714A ITUB20153714A1 (en) 2015-09-18 2015-09-18 Thymosine alfa 1 for use in the treatment of cystic fibrosis.

Publications (1)

Publication Number Publication Date
ITUB20153714A1 true ITUB20153714A1 (en) 2017-03-18

Family

ID=54780428

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUB2015A003714A ITUB20153714A1 (en) 2015-02-09 2015-09-18 Thymosine alfa 1 for use in the treatment of cystic fibrosis.

Country Status (1)

Country Link
IT (1) ITUB20153714A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087067A2 (en) * 2003-03-28 2004-10-14 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
WO2006101740A2 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087067A2 (en) * 2003-03-28 2004-10-14 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
WO2006101740A2 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALLAN L GOLDSTEIN ET AL: "From lab to bedside: emerging clinical applications of thymosin [alpha]1", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, ASHLEY, LONDON; GB, vol. 9, no. 5, 1 May 2009 (2009-05-01), pages 593 - 608, XP009182082, ISSN: 1471-2598, DOI: 10.1517/14712590902911412 *
B. H. SEGAL ET AL: "Immunotherapy for Fungal Infections", CLINICAL INFECTIOUS DISEASES, vol. 42, no. 4, 15 February 2006 (2006-02-15), US, pages 507 - 515, XP055258778, ISSN: 1058-4838, DOI: 10.1086/499811 *
DAVID A. STEVENS ET AL: "Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis-State of the Art: Cystic Fibrosis Foundation Consensus Conference", CLINICAL INFECTIOUS DISEASES, vol. 37, no. s3, 1 October 2003 (2003-10-01), US, pages S225 - S264, XP055258780, ISSN: 1058-4838, DOI: 10.1086/376525 *
LUIGINA ROMANI ET AL: "Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling", BLOOD, vol. 103, no. 11, 24 February 2004 (2004-02-24), pages 4232 - 4239, XP055259171, DOI: 10.1182/blood- *
NAEL A. MCCARTY ET AL: "A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis", PEDIATRIC PULMONOLOGY., vol. 33, no. 2, 15 February 2002 (2002-02-15), US, pages 90 - 98, XP055258874, ISSN: 8755-6863, DOI: 10.1002/ppul.10041 *
ROBERTO CAMERINI ET AL: "Historical review of thymosin [alpha] 1 in infectious diseases", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 15, no. sup1, 30 June 2015 (2015-06-30), ASHLEY, LONDON; GB, pages 117 - 127, XP055258912, ISSN: 1471-2598, DOI: 10.1517/14712598.2015.1033393 *
SHAWN D. AARON ET AL: "Treatment of Aspergillus fumigatus in Patients with Cystic Fibrosis: A Randomized, Placebo-Controlled Pilot Study", PLOS ONE, vol. 7, no. 4, 30 April 2012 (2012-04-30), pages e36077, XP055258883, DOI: 10.1371/journal.pone.0036077 *

Similar Documents

Publication Publication Date Title
JP2016028092A5 (en)
JP2016065085A5 (en)
CL2020000173S1 (en) Massager
HK1252645A1 (en) Massager
DK3112682T3 (en) Eccentric screw pump with mounting through the hollow rotor.
BR112018005409A2 (en) glycodirectional therapy.
DK3329118T3 (en) IMPROVEMENTS IN THE WINDOW EXPERIENCE
DK3393478T3 (en) combination therapy
KR20180084876A (en) The plasma-
DK3408265T3 (en) THERAPEUTIC RELATIONS
GB201707503D0 (en) New Therapy 3
GB201707501D0 (en) New therapy 2
JP2017528459A5 (en)
DK3445722T3 (en) PEF CHAMBER
FI11211U1 (en) The press apparatus
JP2016047837A5 (en)
GB2572106B (en) Anti-water-ingress lotion pump
DK3795130T3 (en) THERAPY APPARATUS.
ITUB20153714A1 (en) Thymosine alfa 1 for use in the treatment of cystic fibrosis.
DE102016113775B8 (en) Back Massager
TWM533983U (en) Massager structure
FI11201U1 (en) The power electronics unit
DK3597169T3 (en) SAUNA
UA38402S (en) MASSAGE MAT-TRACK
ZAA201801222S (en) Massager